DNAprint Genomics (DNAG)

[Preciouslife1]

23andMe is a privately held company run by and founded by one of the Google Boy's wives and is a Genomics company specializing in personalized medicine.....Hmmmmmmm!

http://23andme.com/

http://23andme.com/about.html

23andMe is a privately held company developing new ways to help you make sense of your own genetic information.

Even though your body contains trillions of copies of your genome, you've likely never read any of it. Our goal is to connect you to the 23 paired volumes of your own genetic blueprint (plus your mitochondrial DNA), bringing you personal insight into ancestry, genealogy, and inherited traits. By connecting you to others, we can also help put your genome into the larger context of human commonality and diversity.

Toward this goal, we are building on recent advances in DNA analysis technologies to enable broad, secure, and private access to trustworthy and accurate individual genetic information. Combined with educational and scientific resources with which to interpret and understand it, your genome will soon become personal in a whole new way.

To hear about new developments as they happen, sign up here:
______________________________________________________________.

Board of Directors

Linda has over 20 years of sales and business development experience in the biopharmaceutical industry in San Francisco, Boston, San Diego, and Washington, D.C. Prior to starting 23andMe, she developed translational research collaborations with academic and pharmaceutical partners for Affymetrix and Perlegen Sciences. Linda also spent time at Spotfire helping scientists understand the power of data visualization and at Applied Biosystems during the early days of the human genome project. The advent of high density genome-wide scanning technologies brought huge potential for significant discoveries. However, the lack of sufficient funding to enable adequate studies prompted Linda to think of a new research model. These ideas led to the formation of 23andMe. Her primary interest is the acceleration of personalized medicine, using genetic profiles to target the right drug to the right person at the correct dose. Linda graduated from Augustana College with a B.A. in biology.


Anne brings to 23andMe a 10-year background in healthcare investing, focused primarily on biotechnology companies. Anne left the investing world with the hope that she could have a positive impact on the medical world and the biotechnology industry through 23andMe. From her vantage point, Anne saw a need for creating a way to generate more information—especially more personalized information—so that biotech and pharmaceutical companies could better understand and develop new drugs and diagnostics. By encouraging individuals to access and learn about their own genetic information, 23andMe will create a common, standardized resource that has the potential to accelerate drug discovery and bring personalized medicine to the public. (Plus, getting access to her own genetic information and understanding it has always been one of Anne's ambitions.) Anne graduated from Yale University with a B.S. in biology.


Esther Dyson does business as EDventure, the reclaimed name of the company she owned for 20-odd years before selling it to CNET Networks in 2004.

In the last few years, she has turned her sights on IT and health care, including two issues of Release 1.0, her newsletter (Health and Identity: No Patient Left Behind? in January 2005 and Personal Health Information: Data Comes Alive! in September 2005). Also in September 2005, she ran a seminal Personal Health Information workshop that laid out many of the challenges still bedeviling the health-care community. Currently, she is one of the initial ten subjects of George Church's Personal Genome Project.

Her healthcare investments over the years have included Medscape (board member) and Medstory, recently sold to Microsoft. She is also an investor in Ovusoft, Resilient, and Voxiva (board member), and is an informal advisor to DNA Direct.

Her primary activity is investing in start-ups and guiding many of them as a board member. Her board seats include Boxbe, CVO Group (Hungary), Eventful.com, Evernote, IBS Group (Russia, advisory board), Meetup, Midentity (UK), NewspaperDirect, Yandex (Russia), and WPP Group. Some of her past direct IT investments include Flickr, Del.icio.us, BrightMail, and Orbitz.

For more than 20 years Dyson wrote the newsletter Release 1.0 and ran PC Forum, the IT market's leading executive conference. She sold them to CNET Networks in 2004, and left CNET at the end of 2006. Dyson was the founding chairman of ICANN from 1998 to 2000, and was also chairman of the Electronic Frontier Foundation in the 90's. In 1997, she wrote "Release 2.0 : A Design for Living in the Digital Age," which appeared in paperback a year later as "Release 2.1." In 1994, she wrote a seminal essay on intellectual property for WIRED magazine.

In both her investments and her nonprofit activities, she has always been concerned with the impact of information technology on business and society.